These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37417391)

  • 1. Socioeconomic status, biologics and all-cause mortality.
    Naldi L
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):e1325. PubMed ID: 37417391
    [No Abstract]   [Full Text] [Related]  

  • 2. Socioeconomic status, biologics and all-cause mortality in the VA healthcare system.
    Salahuddin T; Waldo SW
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):e1326-e1327. PubMed ID: 37458526
    [No Abstract]   [Full Text] [Related]  

  • 3. Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania.
    Codreanu C; Popescu CC; Mogoşan C
    Biomed Res Int; 2018; 2018():7458361. PubMed ID: 29854787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic Agents and Secondary Immune Deficiency.
    Axelrod H; Adams M
    Immunol Allergy Clin North Am; 2021 Nov; 41(4):639-652. PubMed ID: 34602234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply to "The confounding effect of baselined characteristics in the assessment of efficacy of biologics".
    Cai S; Xu S; Lou H; Zhang L
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2487-2488. PubMed ID: 36087947
    [No Abstract]   [Full Text] [Related]  

  • 6. The real psoriasis biologics era will take some time in China.
    Zhang Y
    J Dermatolog Treat; 2022 Mar; 33(2):1195-1196. PubMed ID: 32697162
    [No Abstract]   [Full Text] [Related]  

  • 7. How to define a 'super-responder' to biologics in psoriasis studies.
    Thomas SE; van den Reek JMPA; Seyger MMB; de Jong EMGJ
    Br J Dermatol; 2023 Oct; 189(5):621-622. PubMed ID: 37595133
    [No Abstract]   [Full Text] [Related]  

  • 8. Predicting the long-term outcomes of biologics in patients with psoriasis using machine learning.
    Emam S; Du AX; Surmanowicz P; Thomsen SF; Greiner R; Gniadecki R
    Br J Dermatol; 2020 May; 182(5):1305-1307. PubMed ID: 31778205
    [No Abstract]   [Full Text] [Related]  

  • 9. Biologics utilization for psoriasis is lower in black compared with white patients.
    Hodges WT; Bhat T; Raval NS; Herbosa C; Ugwu-Dike P; Kwatra SG; Musiek A; Mann C; Semenov YR
    Br J Dermatol; 2021 Jul; 185(1):207-209. PubMed ID: 33567102
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey of psoriasis patients on biologics during COVID-19: a single centre experience.
    Burlando M; Carmisciano L; Cozzani E; Parodi A
    J Dermatolog Treat; 2022 Feb; 33(1):596. PubMed ID: 32406283
    [No Abstract]   [Full Text] [Related]  

  • 12. First-Line Persistence of Biologics in Psoriasis from a Cohort Based on French Medico-Administrative Data.
    Marcombes C; Penso L; Sbidian E
    J Invest Dermatol; 2023 Sep; 143(9):1819-1822.e3. PubMed ID: 36997111
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologics in pediatric psoriasis and atopic dermatitis: revolutionizing the treatment landscape.
    Scott JB; Paller AS
    Cutis; 2020 Nov; 106(5):224-226;E1;E2. PubMed ID: 33465193
    [No Abstract]   [Full Text] [Related]  

  • 14. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience.
    Ruggiero A; Martora F; Picone V; Potestio L; Camela E; Battista T; Fabbrocini G; Megna M
    Clin Exp Dermatol; 2022 Dec; 47(12):2280-2282. PubMed ID: 35867020
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.
    Roccuzzo G; Mastorino L; Susca S; Cariti C; Passerini SG; Sciamarrelli N; Borriello S; Macagno N; Sliquini N; Avallone G; Verrone A; Stroppiana E; Quaglino P; Ortoncelli M; Dapavo P; Ribero S
    Clin Exp Dermatol; 2023 Mar; 48(4):379-381. PubMed ID: 36745578
    [No Abstract]   [Full Text] [Related]  

  • 16. Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study.
    Nielsen ML; Thein D; Rasmussen MK; Bertelsen T; Dam TN; Skov L; Bryld LE; Wu JJ; Thomsen SF; Thyssen JP; Egeberg A
    J Am Acad Dermatol; 2023 Jun; 88(6):1378-1381. PubMed ID: 36739903
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics.
    Megna M; Potestio L; Battista T; Camela E; Genco L; Noto M; Fabbrocini G; Martora F
    Clin Exp Dermatol; 2022 Dec; 47(12):2310-2312. PubMed ID: 36052835
    [No Abstract]   [Full Text] [Related]  

  • 18. Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy.
    Vuyyuru SK; Brahmania M; Arab JP; Jairath V
    Inflamm Bowel Dis; 2022 Dec; 28(12):e150-e152. PubMed ID: 36173888
    [No Abstract]   [Full Text] [Related]  

  • 19. Fresh from the biotech pipeline: fewer approvals, but biologics gain share.
    Senior M
    Nat Biotechnol; 2023 Feb; 41(2):174-182. PubMed ID: 36624153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to "Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy".
    Safarpour AR; Shojaei-Zarghani S; Mehrabi M; Keshtkar AA; Oroojan AA; Sivandzadeh GR
    Inflamm Bowel Dis; 2022 Dec; 28(12):e153. PubMed ID: 36173869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.